SCHEMBL23218127

SCHEMBL23218127

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C(F)F)oc2c(NCC3CC3)cc(Cl)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
GPR35 Q9HC97 2/20 0.34
PTGS2 P35354 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
POLB P06746 2/20 0.32
ALDH1A1 P00352 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
PTGER4 P35408 1/20 0.32
HTT P42858 1/20 0.32
LRRK2 Q5S007 1/20 0.32
MAPT P10636 3/20 0.31
KDM4E B2RXH2 2/20 0.31
PKM P14618 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852959 1.00 CNR1 (0.35) CNR1CNR2RAB9ANPC1GPR35
SCHEMBL23218350 0.93 CNR1 (0.36) CNR1CNR2RAB9ANPC1GPR35
SCHEMBL29852876 0.93 CNR1 (0.36) CNR1CNR2RAB9ANPC1GPR35
SCHEMBL29852727 0.91 CNR1 (0.37) CNR1CNR2RAB9ANPC1GPR35
SCHEMBL23218501 0.91 CNR1 (0.37) CNR1CNR2RAB9ANPC1GPR35
SCHEMBL23218374 0.86 MEN1 (0.36) RAB9ANPC1PTGS2MEN1KMT2A
SCHEMBL29591409 0.86 MEN1 (0.36) RAB9ANPC1PTGS2MEN1KMT2A
SCHEMBL29853001 0.86 MEN1 (0.36) RAB9ANPC1PTGS2MEN1KMT2A
SCHEMBL23218176 0.85 CFD (0.36) CNR1CNR2MEN1KMT2APTGER4
SCHEMBL29853028 0.85 CFD (0.36) CNR1CNR2MEN1KMT2APTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CNR1 454/4885CNR2 312/4885RAB9A 1922/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CNR1 2437/4885CNR2 2888/4885RAB9A 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.